Quarterly report pursuant to Section 13 or 15(d)

Related Party Transactions (Tables)

v3.7.0.1
Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2017
Related Party Transactions [Abstract]  
Schedule of Effective Date and Equity Fee Payble
The following table summarizes, by subsidiary, the effective date of the Founders Agreements and PIK dividend or equity fee payable to the Company in accordance with the terms of the Founders Agreements, Exchange Agreements and the subsidaries’ certificates of incorporation.
 
 
 
 
 
PIK Dividend as
 
 
 
 
 
 
 
a % of fully
 
 
 
 
 
 
 
diluted
 
 
 
 
 
 
 
outstanding
 
Class of Stock
 
Fortress Company
 
Effective Date (1)
 
capitalization
 
Issued
 
Helocyte
 
March 20, 2015
 
 
2.5
%
Common Stock
 
Avenue
 
February 17, 2015
 
 
2.5
%
Common Stock
 
Mustang
 
March 13, 2015
 
 
2.5
%
Common Stock
 
Checkpoint
 
March 17, 2015
 
 
0.0
%(2)
Common Stock
 
Cellvation
 
October 31, 2016
 
 
2.5
%
Common Stock
 
Caelum
 
January 1, 2017
 
 
2.5
%
Common Stock
 
Cyprium
 
March 13, 2017
 
 
2.5
%
Common Stock
 
 
(1) – Represents the effective date of each subsidiary’s Founders Agreement. While certain Founders Agreements may have been amended and restated subsequently, as described in the Company’s Form 10-K for the year ended December 31, 2016 filed with the SEC on March 16, 2017, each PIK dividend and equity fee is payable on the annual anniversary of the effective date of the original Founders Agreement.
 
(2) – Instead of a PIK dividend, Checkpoint pays the Company an annual equity fee in shares of Checkpoint’s common stock equal to 2.5% of Checkpoint’s fully diluted outstanding capitalization.
Schedule of The Effective Date and Annual Management Services agreement Fee Income Expense
The following table summarizes, by subsidiary, the effective date of the MSA and the annual consulting fee payable by the subsidiary to the Company in quarterly installments:
 
($ in thousands)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fortress
 
 
 
 
 
 
 
Annual MSA Fee
 
Company
 
Effective Date
 
R&D
 
G&A
 
(Income)/Expense
 
Helocyte
 
March 20, 2015
 
$
250
 
$
250
 
$
500
 
Avenue
 
February 17, 2015
 
 
250
 
 
250
 
 
500
 
Mustang
 
March 13, 2015
 
 
250
 
 
250
 
 
500
 
Checkpoint
 
March 17, 2015
 
 
250
 
 
250
 
 
500
 
Cellvation
 
October 31, 2016
 
 
250
 
 
250
 
 
500
 
Caelum
 
January 1, 2017
 
 
250
 
 
250
 
 
500
 
Cyprium
 
March 13, 2017
 
 
250
 
 
250
 
 
500
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fortress
 
 
 
 
(1,750)
 
 
(1,750)
 
 
(3,500)
 
Consolidated (Income)/Expense
 
$
-
 
$
-
 
$
-